Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 9, pp 17–19 | Cite as

Recent R&D Highlights

News & View

Focusing on cancer

Celecoxib analog halts tumor growth

Researchers at from the University of Southern California (USC) have been studying the effects of 2,5-dimethyl-celecoxib (DMC), a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex®; Pfizer) that lacks the ability to block the activity of COX-2, an enzyme integral to the inflammatory process.[1] Their work shows that DMC is a potent tumor fighter, able to halt tumor growth even in drug-resistant lines of multiple myeloma cells1

The COX-2 inhibitors have attracted headlines mostly as a result of their anti-inflammatory effects — and more recently because of the market withdrawal of two agents in this drug class.2However, celecoxib is more than just an anti-inflammatory agent. Over the past couple of years, researchers have begun to recognize that COX-2 can sometimes play a role in cancer; for example, studies have shown that the enzyme is overexpressed by multiple myeloma cells and that...


  1. 1.
    University of Southern California. USC researchers find drug is tough tumor fighter. Media release: 29 Aug 2005Google Scholar
  2. 2.
    Burnham Institute. Cancer drug target Chk1 may also be source of drug resistance. Media release: 2 Sep 2005Google Scholar
  3. 3.
    University of Texas M. D. Anderson Cancer Center. Phase I cancer findings under-reported. Media release: 22 Aug 2005Google Scholar
  4. 4.
    Rosetta Inpharmatics. FDA LICENSES THE Rosetta Resolver(R) System for use in the Center for Drug Evaluation and Research. Media release: 24 Aug 2005Google Scholar
  5. 5.
    EurekAlert. IMEx consortium provides new mechanism for improving access to molecular interaction data. Media release: 29 Aug 2005Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations